Measuring small molecules (metabolites) in blood and urine that predict the response to immunotherapy in lung cancer patients
| ISRCTN | ISRCTN98848959 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN98848959 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Protocol serial number | Nil known |
| Sponsor | Instituto de Salud Carlos III |
| Funder | Instituto de Salud Carlos III |
- Submission date
- 15/07/2020
- Registration date
- 17/07/2020
- Last edited
- 29/01/2025
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Plain English summary of protocol
Background and study aims
Immunotherapy is a cancer treatment that uses the body's immune system to fight cancer in advanced stages. Despite the success of immunotherapy, there are still several barriers to extending its clinical benefit to a greater number of patients. Although there are patients who respond well to immunotherapy, some patients do not respond to the same treatment. At present, it is not well understood how and why this occurs. The ability to predict the response to immunotherapy should allow the development of personalized treatments, improve survival rates and reduce unnecessary exposure of patients to toxic medications. To achieve this, this study will evaluate a wide range of small molecules (metabolites) in blood and urine using different techniques and try to identify which metabolites are useful for predicting the response to treatment.
Who can participate?
Patients aged over 18 with stage III and IV non-small cell lung cancer, who are candidates for immunotherapy treatment
What does the study involve?
This study involves first-line treatments with immunotherapy exclusively or immunotherapy combined with chemotherapy, and second-line immunotherapy treatments after a chemotherapy-based first-line treatment. Fasting morning blood and urine samples will be collected and metabolites will be measured before and after immunotherapy.
What are the possible benefits and risks of participating?
Potential benefits of participating are a good response to immunotherapy and improvement of survival rates. The possible risks of participating include treatment toxicities or deterioration of performance status and disease progression.
Where is the study run from?
University Hospital Sant Joan de Reus (Spain)
When is the study starting and how long is it expected to run for?
September 2020 to December 2022
Who is funding the study?
Instituto de Salud Carlos III (Spain)
Who is the main contact?
Dr Christopher Papandreou
papchris10@gmail.com
Contact information
Scientific
St/Sant Llorenç 21
Reus
-
Spain
 ORCID ID |
0000-0002-6803-507X |
|---|---|
| Phone | +34 (0)638910914 |
| papchris10@gmail.com |
Scientific
Avinguda Josep Laporte, 2.
Reus
43204
Spain
| Phone | +34 (0)629392561 |
|---|---|
| josep.guma@salutsantjoan.cat |
Study information
| Primary study design | Observational |
|---|---|
| Study design | Prospective observational single-centre study |
| Secondary study design | Longitudinal study |
| Study type | Participant information sheet |
| Scientific title | Metabolomic profiles in blood and urine as predictors of response to immunotherapy in lung cancer patients |
| Study acronym | MetLung |
| Study objectives | The hypothesis of this proposal is that specific metabolites in blood and urine predict the response to immunotherapy. The researchers also hypothesize that immunotherapy will modulate specific metabolites in blood and urine differently in responders than in non-responders. |
| Ethics approval(s) | Approved 09/04/2020, Institut d'Investigació Sanitària Pere Virgili (IISPV) - Ethical Committee (Hospital Universitaria Sant Joan. Avda. Josep Laporte, 2. Planta 0 - E2 43204 Reus, Hospital Universitari de Tarragona Joan XXII. c/ Doctor Mallafrè, 4 Parc Sanitari Hosp.Joan XXIII, 43005 Tarragona; +34 (0)977 759 395; ceim@iispv.cat), ref: CEIm: 072/2020 |
| Health condition(s) or problem(s) studied | Locally advanced or metastatic non-small cell lung cancer |
| Intervention | First-line treatments with immunotherapy exclusively (those whose tumours express more than 50% of PDL1) or immunotherapy combined with chemotherapy (expression of PDL1 between 1 and 49%), and second-line immunotherapy treatments after a chemotherapy-based first line. For the metabolomic analysis in blood and urine samples, different analytic platforms will be used according to the sample. Three different metabolomics platforms will be used: proton nuclear magnetic resonance (1H NMR), liquid chromatography coupled to mass spectrometry (LC-MS) and gas chromatography coupled to mass spectrometry (GC-MS). Targeted and untargeted metabolomics will also be performed in blood and urine samples. The duration of follow-up will be 12 weeks. |
| Intervention type | Other |
| Primary outcome measure(s) |
Metabolites in blood and urine will be measured using targeted and untargeted approaches, and 1H NMR, LC-MS and GC-MS analytical techniques at baseline and 12 weeks |
| Key secondary outcome measure(s) |
1. Toxicity assessment reflected in the medical history, classifying it by affected organ and by degree of severity (1-4) based on ESMO clinical practice guidelines, performed at 12 weeks |
| Completion date | 31/12/2022 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 180 |
| Total final enrolment | 131 |
| Key inclusion criteria | Patients older than 18 years with stage III and IV NSCLC candidates for immunotherapy treatment |
| Key exclusion criteria | 1. Patients with another primary malignancy diagnosed in the previous 5 years (except for cervical carcinoma in situ and non-melanoma skin cancer) 2. Patients with tumours expressing actionable mutations in EGFR, ALK or ROS1 3. Patients with stage IV severe kidney disease (creatinine clearance < 30 ml/min) 4. Patients with severe liver disease (hepatitis, cirrhosis) 5. Patients with low Performance Status (ECOG 3-4) 6. Patients who refuse to sign the informed consent 7. Any previous systemic immunotherapeutic treatment will also make the patient ineligible for the study |
| Date of first enrolment | 01/09/2020 |
| Date of final enrolment | 31/12/2022 |
Locations
Countries of recruitment
- Spain
Study participating centres
Reus
43204
Spain
Reus
43204
Spain
Tarragona
43003
Spain
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan summary | Available on request |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Christopher Papandreou (papchris10@gmail.com). |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
29/01/2025: The following changes were made:
1. The overall study end date was changed from 31/12/2023 to 31/12/2022.
2. The intention to publish date was changed from 06/08/2024 to 01/12/2025.
03/01/2023: The contact confirmed the record is up to date.
03/01/2023: The final enrolment number has been added.
18/11/2021: A contact email was changed.
08/11/2021: The recruitment end date was changed from 31/08/2022 to 31/12/2022.
12/08/2020: Primary outcome measure updated.
03/08/2020: The sponsor and funder were changed from Institut d'Investigació Sanitària Pere Virgili to Instituto de Salud Carlos III.
16/07/2020: Trial's existence confirmed by Institut d'Investigació Sanitària Pere Virgili.
